191 related articles for article (PubMed ID: 30184524)
1. Sunitinib or Sorafenib as Neoadjuvant Therapy May not Improve the Survival Outcomes of Renal Cell Carcinoma with Tumor Thrombus.
Cai W; Huang J; Yuan Y; Hu X; Li M; Kong W; Zhang J; Guo J; Chen Y; Huang Y
Urol Int; 2018; 101(4):391-399. PubMed ID: 30184524
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Sunitinib Decreases Inferior Vena Caval Thrombus Size and Is Associated With Improved Oncologic Outcomes: A Multicenter Comparative Analysis.
Field CA; Cotta BH; Jimenez J; Lane BR; Yim K; Lee HJ; Ryan ST; Hamilton ZA; Patel S; Wang S; Kane CJ; Dey S; Mckay RR; Noyes S; Millard FE; Rini BI; Campbell SC; Derweesh IH
Clin Genitourin Cancer; 2019 Jun; 17(3):e505-e512. PubMed ID: 30808547
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
4. Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study.
Cai W; Cai B; Zhou J; Chen Y; Zhang J; Huang Y; Xue W; Huang J
Cancer Commun (Lond); 2019 Oct; 39(1):56. PubMed ID: 31601263
[No Abstract] [Full Text] [Related]
5. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
[TBL] [Abstract][Full Text] [Related]
6. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes of 42 Renal Cell Carcinoma Patients With Metastases Solely to the Lung Who Received Sorafenib as Second-line Systemic Therapy.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2019 Feb; 39(2):1067-1072. PubMed ID: 30711996
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic effects and associated adverse events of first-line treatments of advanced renal cell carcinoma (RCC): a meta-analysis.
Wang L; Ma L; Wang X; Li B; Guo S; Qiao Q
Int Urol Nephrol; 2015 Apr; 47(4):617-24. PubMed ID: 25686740
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib versus sorafenib for patients with advanced renal cell carcinoma with renal impairment before the immune-oncology therapy era.
Takayama T; Kubo T; Yamazaki M; Takeshima S; Komatsubara M; Kameda T; Kamei J; Sugihara T; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Jpn J Clin Oncol; 2019 Dec; 49(12):1164-1171. PubMed ID: 31665407
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis.
Liu XL; Xue HY; Chu Q; Liu JY; Li J
Medicine (Baltimore); 2020 Mar; 99(13):e19570. PubMed ID: 32221075
[TBL] [Abstract][Full Text] [Related]
13. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study.
Martín-Aguilar AE; Núñez-López H; Ramirez-Sandoval JC
BMC Cancer; 2021 Jan; 21(1):16. PubMed ID: 33402115
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.
Vogelzang NJ; Pal SK; Ghate SR; Swallow E; Li N; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
Adv Ther; 2017 Nov; 34(11):2452-2465. PubMed ID: 29076108
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
17. Association between age and sex and mortality after adjuvant therapy for renal cancer.
Mamtani R; Wang XV; Gyawali B; DiPaola RS; Epperson CN; Haas NB; Dutcher JP
Cancer; 2019 May; 125(10):1637-1644. PubMed ID: 30620389
[TBL] [Abstract][Full Text] [Related]
18. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Porta C; Procopio G; Cartenì G; Sabbatini R; Bearz A; Chiappino I; Ruggeri EM; Re GL; Ricotta R; Zustovich F; Landi L; Calcagno A; Imarisio I; Verzoni E; Rizzo M; Paglino C; Guadalupi V; Bajetta E
BJU Int; 2011 Oct; 108(8 Pt 2):E250-7. PubMed ID: 21599821
[TBL] [Abstract][Full Text] [Related]
19. Sequential sorafenib and sunitinib for renal cell carcinoma.
Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
[TBL] [Abstract][Full Text] [Related]
20. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
